MRD testing, which stands for measurable or minimal residual disease testing, is a very sensitive test that looks for the handful of cancer cells, or the traces of tumor DNA in the blood, that can still be around after treatment. We’re talking about amounts so small that a CT scan, an MRI or even a pathologist’s microscope can come back looking completely clean. So if you’ve ever typed “what is MRD testing” into a search bar, here’s the plain version: it’s the follow-up question to a clear scan. Fine, nothing is visible, but is anything still there? It has been routine in blood cancers like leukemia and lymphoma for a long time. In solid tumors such as colon or breast cancer, the blood based version is newer, and doctors are still working out where exactly it earns its place.
Dr. Sandeep Nayak, who provides cancer treatment in Bangalore with over 24 years of experience, says, “A clear scan after surgery is good news, no question. But a scan only shows what is big enough to see, and patients walk out of that room still wondering if something is hiding. MRD testing is an attempt to answer that. I’d add one caution though. It’s an extra piece of information, not a verdict, and it only means something when we read it together with the scans, the pathology report and how the patient is actually doing.”
Finished treatment and unsure what follow-up should look like? Ask your oncologist which tests and scans are right for your cancer type and stage.
MRD Testing vs Standard Scans: How Do They Compare?
Scans haven’t gone anywhere. After something like colon cancer treatment, CT, MRI and PET still do the heavy lifting in follow-up. MRD testing is an add-on, and this is how the two stack up.
|
MRD Testing |
Standard Imaging (CT, MRI, PET) |
|
|
What it looks for |
Traces of cancer cells or tumor DNA |
Visible tumors or changes in organs |
|
Sample needed |
Blood draw, or bone marrow in blood cancers |
A scan, often with contrast dye |
|
Sensitivity |
Can pick up amounts far too small to see |
Needs a lesion big enough to show up |
|
Timing |
May flag a problem months before a scan could |
Shows disease once it has grown enough |
|
Tells you where? |
No, only that disease is likely present |
Yes, shows location and size |
|
Radiation |
None |
CT and PET use radiation |
|
Current role |
Added layer, still evolving for solid tumors |
Standard for staging and follow-up |
Curious what coming back actually looks like at each stage? Our stage 0 to stage 4 colon cancer guide walks through it, including what recurrence means.
Where Does Minimal Residual Disease Testing Fit in Cancer Care?
- In leukemia and lymphoma it has been standard for years. It tells doctors how deep the response to treatment really went.
- Solid tumors are murkier. Researchers are testing whether a blood test after surgery can show who might relapse in colon cancer or breast cancer, and who could skip extra chemotherapy. Nothing is settled yet.
- Repeat tests during follow-up can catch a rising signal early. A few small colorectal studies found tumor DNA in the blood before the scan showed anything.
- A negative result helps but doesn’t close the case. Some tumors barely shed any DNA, so they can slip past.
- The awkward one is a positive test with a clean scan. It hints at higher risk, and for plenty of cancers nobody has agreed on the next step. The tumour board works that out case by case.
- Not every lab offers it, prices vary, and it won’t suit every cancer. Still hunting for the right doctor to ask? Our piece on how to choose a cancer surgeon in Bangalore covers what to look for.
What Determines the Right Treatment Approach?
The right cancer treatment approach depends on the type and stage of cancer, previous treatments, and the patient’s overall health. For some cancers, minimal residual disease (MRD) testing can help guide treatment decisions and monitor response, but its usefulness varies by cancer type.
Cancer type and stage. The type of cancer and how far it has progressed help determine which treatments are most appropriate.
Previous treatment and response. Surgery, chemotherapy, radiation, or targeted therapy can influence the next steps in care.
MRD test results. When supported by evidence for a particular cancer, MRD results may help doctors assess whether cancer cells remain and whether treatment adjustments should be considered.
Available treatment options. The medical team evaluates whether additional treatment, continued monitoring, or a change in therapy is appropriate.
Overall health and patient preferences. Age, other health conditions, treatment tolerance, and personal preferences also influence the treatment plan.
Multidisciplinary review. A tumour board brings specialists together to review the patient’s condition and recommend an individualised treatment strategy.
Key Takeaways
- Follow-up after treatment is a planned part of care, not guesswork.
- Whether MRD testing is worthwhile depends on cancer type, stage, prior treatment and how strong the evidence is.
- A test is most useful when its result could change what happens next.
- Many MRD tests are still being studied, so ask your team what the result would mean for you.
- For questions about your own follow-up, you can contact the clinic at +91 9482202240.
FAQs
What is MRD testing in simple words?
It’s a very sensitive test that checks whether a few cancer cells, or bits of tumor DNA, are still in your body after treatment, even when scans look clear. For solid tumors it’s usually a blood draw. In blood cancers, a bone marrow sample is sometimes used.
Is MRD testing the same as cancer screening?
No. Screening looks for cancer in people who haven’t had it. MRD testing is for people who have already been treated and want to know whether anything is left behind.
If my MRD test is negative, am I cured?
Not necessarily. A negative result is good news, but it can’t promise the cancer won’t return. Some tumors release very little DNA and the test can miss them, which is why it’s read alongside scans and regular check-ups.
Does minimal residual disease testing work for every cancer?
No. It’s most established in blood cancers like leukemia and lymphoma. For solid tumors such as colon and breast cancer, blood based tests are newer, and how much they should change treatment is still being studied.
Reference
- National Cancer Institute. Minimal residual disease (NCI Dictionary of Cancer Terms)
- Oncotarget. Detection of circulating tumor DNA in patients of operative colorectal and gastric cancers
Disclaimer:
This content is published for educational and informational purposes only and is not a substitute for medical advice. Please consult your doctor before changing any treatment.